Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anito-cel in Generalized Myasthenia Gravis
NCT06626919Phase 1Recruiting
- Sponsor
- Kite Pharma
- Start
- Apr 2025
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of anitocabtagene autoleucel in myasthenia gravis (MG) (2 arms), sponsored by Kite Pharma. Primary endpoints: Percentage of Participants Experiencing Treatment-Emergent Adverse Events at 24 months, Percentage of Participants Experiencing Dose-Limiting Toxicities at 28 days and 3 more. Started Apr 2025; status: recruiting.
02
Drugs
anitocabtagene autoleucel
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06626919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626919.